Clinical trials: Immunomodulatory Drugs, active
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple…
- Trial name
- NCT04764942
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Ventricular Arrythmia, Non-ischemic Cardiomyopathy
Comparing Immune System Suppression to Medication for Unexplained Heart Function and Irregular Heartbeat
Ventricular tachycardia (VT, a potentially fatal condition where the ventricle of the heart beats rapidly) superimposed on non-ischemic cardiomyopathy (NICM, a disease of heart with broad etiologies except coronary artery…
- Conditions
- Ventricular Arrythmia, Non-ischemic Cardiomyopathy, Arrhythmogenic Inflammatory Cardiomyopathy
- Trial name
- IMMUNE VT (NCT06635863)
- Testing
- Prednisone 40mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roderick Tung
Multiple Myeloma, New Diagnosis Tumor
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- KRdvsRd (NCT04096066)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 40 sites in Italy
- Volunteers
- 84 people
- Sponsor
- Fondazione EMN Italy Onlus
High-risk Lung Nodules
Immunoprevention for High-risk Lung Lesions
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
- Trial name
- NCT07284485
- Testing
- Nadunolimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Robert Samstein
Multiple Myeloma, Deletion 17P Syndrome
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
Multiple myeloma (MM) with chromosome 17 deletion (del(17p) represents one of the most dangerous genetic variant of this disease, since it is associated with a high level of genomic instability.
- Trial name
- DPd (NCT04124497)
- Testing
- Daratumumab, Pomalidomide, Dexamethasone
- Where
- 15 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione EMN Italy Onlus
Peripheral T-Cell Lymphoma Refractory
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
This study will test whether a combination of two medicines, zilovertamab vedotin (ZV) and lenalidomide, can help people with peripheral T-cell lymphoma that has come back after treatment or has not responded to previous…
- Trial name
- ZiVLen (NCT07913594)
- Testing
- Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide
- Where
- 5 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Multiple Myeloma
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help.
- Trial name
- NCT04933539
- Testing
- Dexamethasone, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India.
- Trial name
- NCT07881835
- Testing
- Elranatamab
- Volunteers
- 75 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, ICI-refractory
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
- Trial name
- NCT07133425
- Testing
- SAR445877
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Pregnancy Related, Immune-mediated Diseases
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
What is this project about? This project aims to better understand how the immune system develops in babies whose mothers received immunomodulatory treatments during pregnancy.
- Trial name
- NEWbornIMMPACT (NCT07033663)
- Testing
- Monoclonal antibody
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundació Sant Joan de Déu
Relapsing Polychondritis
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
- Trial name
- PROSECT RP (NCT06941376)
- Testing
- Methotrexate (MTX), Azathioprine (AZA), Adalimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
IgA Nephropathy, Kidney Transplant Recipients
MYTP01 for Immune-Mediated Diseases
The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for…
- Conditions
- IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy
- Trial name
- NCT07901764
- Testing
- MYTP01
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang Provincial People's Hospital